At present, various of cytokine inhibitors have been applied in the CS treatment, including IL-6-antagonists (i.e., siltuximab), IL-1-antagonists (i.e., anakinra), IL-17-antagonists (i.e., secukinumab), TNF-α-blockers (i.e., infliximab), and INF-α-inhibitors (i.e., sifalimumab), as well as immunomodulators glucocorticoids (Li et al., 2020b), (Ye et al., 2020). This evidence concerns the gene IL1A and Cowden syndrome 1.